Track CALC and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
CalciMedica, Inc. Common Stock
505 Coast Boulevard South, La Jolla, CA, United States, 92037
IPO
2020
Employees
16
Industry
Biotechnology
Sector
Healthcare
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q3 20251+18
19
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0